XML 106 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue
 12 Months Ended
Apr. 24, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include hospitals, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations.
The table below illustrates net sales by segment and division for fiscal years 2020, 2019, and 2018:
 
 Net Sales by Fiscal Year(1)
(in millions)202020192018
Cardiac Rhythm & Heart Failure$5,141  $5,849  $5,947  
Coronary & Structural Heart3,541  3,730  3,562  
Aortic, Peripheral & Venous1,786  1,926  1,845  
Cardiac and Vascular Group10,468  11,505  11,354  
Surgical Innovations5,513  5,753  5,537  
Respiratory, Gastrointestinal, & Renal2,839  2,725  3,179  
Minimally Invasive Therapies Group8,352  8,478  8,716  
Brain Therapies2,922  2,938  2,354  
Spine2,503  2,654  2,668  
Specialty Therapies1,193  1,307  1,556  
Pain Therapies1,107  1,284  1,165  
Restorative Therapies Group7,725  8,183  7,743  
Diabetes Group2,368  2,391  2,140  
Total$28,913  $30,557  $29,953  
(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
The table below includes net sales by market geography and segment for fiscal years 2020, 2019, and 2018:
 Net Sales by Fiscal Year(4)
(in millions)202020192018
U.S.(1)
$5,062  $5,750  $5,681  
Non-U.S. Developed Markets(2)
3,5193,7673,790
Emerging Markets(3)
1,8871,9881,883
Cardiac and Vascular Group10,46811,50511,354
U.S.(1)
3,5323,6303,804
Non-U.S. Developed Markets(2)
3,1693,2503,378
Emerging Markets(3)
1,6511,5981,534
Minimally Invasive Therapies Group8,3528,4788,716
U.S.(1)
5,1225,4785,164
Non-U.S. Developed Markets(2)
1,6591,7591,720
Emerging Markets(3)
945946859
Restorative Therapies Group7,7258,1837,743
U.S.(1)
1,2041,3361,226
Non-U.S. Developed Markets(2)
940855739
Emerging Markets(3)
224200175
Diabetes Group2,3682,3912,140
U.S.(1)
14,91916,19415,875
Non-U.S. Developed Markets(2)
9,2879,6319,627
Emerging Markets(3)
4,7074,7324,451
Total $28,913  $30,557  $29,953  
(1)U.S. includes the United States and U.S. territories.
(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.
(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.
(4)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
At April 24, 2020, $706 million of rebates were classified as other accrued expenses and $321 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 26, 2019, $764 million of rebates were classified as other accrued expenses and $432 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. During fiscal year 2020, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material.
Deferred Revenue and Remaining Performance Obligations
Deferred revenue at April 24, 2020 and April 26, 2019 was $303 million and $315 million, respectively. At April 24, 2020 and April 26, 2019, $213 million and $211 million was included in other accrued expenses, respectively, and $90 million and $104 million was included in other liabilities, respectively. During the fiscal year ended April 24, 2020, the Company recognized $220 million of revenue that was included in deferred revenue as of April 26, 2019.
At April 24, 2020, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more was approximately $1.1 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next four years.